301015 百洋医药
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入3,559,510-5.11%7,506,5158,094,4588,255,9987,509,618
减:营业总成本3,218,418-6.12%6,840,2487,169,3377,256,7826,832,016
    其中:营业成本2,141,407-10.14%4,693,7295,220,6605,507,1525,424,874
               财务费用61,97625.17%107,63171,10965,61348,385
               资产减值损失(9,816)-72.42%(47,107)(16,023)1,911(1,160)
公允价值变动收益(2,121)-91.76%73,3561,716616(10,750)
投资收益(2,819)-81.75%19,59759,20944,5911,877
    其中:对联营企业和合营企业的投资收益(1,156)-91.62%7,19351,12118,87415,601
营业利润339,02627.60%736,266977,7381,043,604674,258
利润总额338,14230.07%722,975966,6281,027,991668,550
减:所得税费用58,19319.83%151,046199,597257,263178,709
净利润279,94832.42%571,929767,031770,728489,841
减:非控股权益55,28014.52%97,24475,43758,667(16,757)
股东净利润224,66837.72%474,685691,593712,061506,598

市场价值指针
每股收益 (元) *0.43038.71%0.9001.3201.3600.960
每股派息 (元) *----0.5710.7620.7620.762
每股净资产 (元) *4.36610.86%4.4964.3294.8874.384
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容